Multiplicom is pleased to announce the release of the BRCA Tumor MASTR Plus molecular assay, research use only, for identification of SNVs in the coding region of BRCA1 and BRCA2 in various types of solid tumors.

The BRCA Tumor MASTR Plus is a molecular assay (research use only) for the identification of all SNVs and/or CNVs in the BRCA1 and BRCA2 genes for patients with breast and ovarian cancer or for individuals with increased risk in breast, ovarian and other cancers. The BRCA Tumor MASTR Plus was developed and tested in close collaborations with leading European diagnostic centers and experts.

Multiplicom’s BRCA Tumor MASTR Plus assay is provided as a ready-to-use kit that offers robust performance with minimum hands-on time. All reagents necessary to enable multiplex amplification of 181 amplicons (123-230 bp) in 4 PCR reactions are included, for full exon coverage. The assay builds on the Multiplicom’s expertise with the BRCA MASTR Dx assay, but is further optimized to detect BRCA1 and BRCA2 mutations in FFPE tumor samples.

The assay can be performed on:
•    DNA purified from FFPE tumor tissue to detect somatic SNVs
•    Blood- (FFT- or DBS-) derived DNA to detect germline SNVs and/or CNVs
The assay is compatible with current Massively Parallel Sequencing (MPS) systems, providing the flexibility to choose your preferred method.